Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 1996;16:1052-1062

This Article
Right arrow Full Text
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jin, F.-Y.
Right arrow Articles by Kashyap, M. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jin, F.-Y.
Right arrow Articles by Kashyap, M. L.
(Arteriosclerosis, Thrombosis, and Vascular Biology. 1996;16:1052-1062.)
© 1996 American Heart Association, Inc.


Articles

Gemfibrozil Stimulates Apolipoprotein A-I Synthesis and Secretion by Stabilization of mRNA Transcripts in Human Hepatoblastoma Cell Line (Hep G2)

Fu-You Jin; Vaijinath S. Kamanna; Mei-Yu Chuang; Kengathevy Morgan; Moti L. Kashyap

the Cholesterol Center, Medical Service, Long Beach (Calif) Department of Veterans Affairs Medical Center, and the University of California, Irvine.

Correspondence to Moti L. Kashyap, MD, Director, Cholesterol Center, Department of Veterans Affairs Medical Center, 5901 E Seventh St (111GE), Long Beach, CA 90822.

Gemfibrozil is a widely used drug that elevates plasma HDL and lowers triglycerides and LDL. The mechanism of action of this pharmacological agent on HDL metabolism is not established. Since the liver is the major organ involved in HDL production and removal, we assessed the effect of gemfibrozil on the modulation of apoA-I (a major protein of HDL)–containing particles by a human hepatoblastoma cell line (Hep G2). Incubation of Hep G2 cells with gemfibrozil resulted in the following statistically significant findings: (1) increased accumulation of apoA-I in the medium without affecting uptake of radiolabeled HDL-protein or HDL–apoA-I; (2) accelerated incorporation of [3H]leucine and [35S]methionine into apoA-I; (3) equivalent increases in [3H]leucine incorporation into HDL particles without and with apoA-II (LpA-I and LpA-I+A-II, respectively); (4) equal efflux of fibroblast cholesterol by harvested LpA-I and LpA-I+A-II particles; (5) increased steady state apoA-I mRNA without affecting apoA-I transcription; and (6) increased apoA-I mRNA half-life (2.2-fold). These data indicate that gemfibrozil stabilizes apoA-I mRNA transcripts, resulting in increased translation of functional apoA-I–containing particles capable of effluxing cellular cholesterol, thus defining a major mechanism by which gemfibrozil increases HDL.


Key Words: atherosclerosis • coronary artery disease • reverse cholesterol transport • cellular cholesterol efflux • apolipoprotein A-I gene expression




This article has been cited by other articles:


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
S. Qin, T. Liu, V. S. Kamanna, and M. L. Kashyap
Pioglitazone Stimulates Apolipoprotein A-I Production Without Affecting HDL Removal in HepG2 Cells: Involvement of PPAR-{alpha}
Arterioscler. Thromb. Vasc. Biol., November 1, 2007; 27(11): 2428 - 2434.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
A. D. Mooradian, M. J. Haas, and N. C. W. Wong
The Effect of Select Nutrients on Serum High-Density Lipoprotein Cholesterol and Apolipoprotein A-I Levels
Endocr. Rev., February 1, 2006; 27(1): 2 - 16.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
H. Duez, B. Lefebvre, P. Poulain, I. P. Torra, F. Percevault, G. Luc, J. M. Peters, F. J. Gonzalez, R. Gineste, S. Helleboid, et al.
Regulation of Human ApoA-I by Gemfibrozil and Fenofibrate Through Selective Peroxisome Proliferator-Activated Receptor {alpha} Modulation
Arterioscler. Thromb. Vasc. Biol., March 1, 2005; 25(3): 585 - 591.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
L. Saucan and E. A. Brinton
Lp A-I and Niacin: New Views of an Antiatherogenic Duo
Arterioscler. Thromb. Vasc. Biol., November 1, 2001; 21(11): 1707 - 1709.
[Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
T. Sakai, V. S. Kamanna, and M. L. Kashyap
Niacin, but Not Gemfibrozil, Selectively Increases LP-AI, a Cardioprotective Subfraction of HDL, in Patients With Low HDL Cholesterol
Arterioscler. Thromb. Vasc. Biol., November 1, 2001; 21(11): 1783 - 1789.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
N. Vu-Dac, S. Chopin-Delannoy, P. Gervois, E. Bonnelye, G. Martin, J.-C. Fruchart, V. Laudet, and B. Staels
The Nuclear Receptors Peroxisome Proliferator-activated Receptor alpha  and Rev-erbalpha Mediate the Species-specific Regulation of Apolipoprotein A-I Expression by Fibrates
J. Biol. Chem., October 2, 1998; 273(40): 25713 - 25720.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
F.-Y. Jin, V. S. Kamanna, and M. L. Kashyap
Estradiol Stimulates Apolipoprotein A-I– but Not A-II–Containing Particle Synthesis and Secretion by Stimulating mRNA Transcription Rate in Hep G2 Cells
Arterioscler. Thromb. Vasc. Biol., June 1, 1998; 18(6): 999 - 1006.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. C. Harnish, M. J. Evans, M. S. Scicchitano, R. A. Bhat, and S. K. Karathanasis
Estrogen Regulation of the Apolipoprotein AI Gene Promoter through Transcription Cofactor Sharing
J. Biol. Chem., April 10, 1998; 273(15): 9270 - 9278.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
F.-Y. Jin, V. S. Kamanna, and M. L. Kashyap
Niacin Decreases Removal of High-Density Lipoprotein Apolipoprotein A-I But Not Cholesterol Ester by Hep G2 Cells : Implication for Reverse Cholesterol Transport
Arterioscler. Thromb. Vasc. Biol., October 1, 1997; 17(10): 2020 - 2028.
[Abstract] [Full Text]